Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. They outperformed the S&P 500 index.
These pharmaceutical giants defied the bear market as investors favored the safety of healthcare. After all, even in a difficult economy, people generally still need their medications. And this means healthcare companies may hold up better than others.
This year, though, AbbVie and J&J aren't off to a strong start. They've both declined. But this might be a buying opportunity. After all, these stocks offer a track record of earnings growth and dividend increases.
Source Fool.com
